Stocktoria

Aligos Therapeutics, Inc. ALGS

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-16 · LEI

Aligos Therapeutics, Inc. statistics & valuation

Market cap$34.5M
P / S15.8×
P / B0.6×
Net margin-1106.7%
Return on equity-45.2%
Return on capital-130.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-1416.20% -3633.60% -1106.70% 2019202020212022202320242025
Gross margin (%)
2019202020212022202320242025
Operating margin (%)
-1423.50% -2469.00% -4024.90% 2019202020212022202320242025
Return on equity (%)
-49.30% -69.50% -92.40% -95.20% -45.20% 2019202020212022202320242025
Shares outstanding
3.9M 38.1M 42.7M 42.9M 3.0M 6.3M 9.9M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-35.70% -40.90% -54.50% -65.50% -57.90% -187.20% -27.30% 2019202020212022202320242025
Free cash flow margin (%)
-1276.30% -2239.60% 2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$2.25 -$34.20 -$20.94 -$2.45 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-4024.9%-2469.0%-1423.5%————
Net margin-1106.7%-3633.6%-1416.2%————
FCF margin—-2239.6%-1276.3%————
Return on assets-27.3%-187.2%-57.9%-65.5%-54.5%-40.9%-35.7%
Return on equity-45.2%452.9%-95.2%-92.4%-69.5%-49.3%80.5%
Current ratio3.902.865.904.035.258.268.70

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.